CoDa Therapeutics, Inc.
News
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
31 May 2010
San Diego, California, May 25, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers...
More...
CoDa Therapeutics Receives Orphan Drug Designation for Nexagon® for the Treatment of Persistent Corneal Epithelial Defects
11 May 2009
May 11. 2009 - CoDa Therapeutics, Inc. today announced that its lead drug product candidate, Nexagon®, has received Orphan Drug Designation from the U.S Food and Drug Administration for the treatment of persistent corneal epithelial defects...
More...
CoDa Therapeutics BPV Press Release
25 Sep 2008
CoDa Therapeutics and BioPacificVentures today announced an investment of US$3 million in CoDa Therapeutics...
More...
CoDa to Begin Clinical Trial
15 May 2008
CoDa Therapeutics has announced that it now has an open IND (Investigational New Drug application) after review by the US FDA (Food and Drug Administration).......
More...
CoDa appoints Chief Operating Officer
28 Feb 2008
Auckland-based CoDaTherapeutics (NZ) Ltd. has announced the promotion of Tracey Sunderland to Chief Operating Officer...
More...
CoDa Therapeutics Scoops First Deal of the Year
12 Mar 2007
Auckland biotech firm CoDa Therapeutics has received the inaugural NZBio Deal of the Year Award, in recognition of the company’s outstanding success over the past 12 months...
More...
CoDa Completes US$20 Million Financing
13 Feb 2007
Biotechnology company CoDa Therapeutics has closed the second half of its initial round of venture capital funding, putting it on target to begin clinical trials...
More...
CoDa Therapeutics Secures $10.0 Million in Additional Series A Financing
2 Feb 2007
CoDa Therapeutics, Inc., today announced a second closing of its Series A financing, receiving $10.0 million in additional venture capital commitments from existing venture investor Domain Associates and new investor GBS Partners.
More...
US Investment for Wound Healing Drug
University of Auckland,7 Nov 2006
A pioneering tissue repair drug discovered by a scientist at The University of Auckland working in collaboration with a colleague at University College London...
More...
CoDa Therapeutics Announces Series A Financing
10 Oct 2006
CoDa Therapeutics, Inc., a biopharmaceutical company founded in 2005, today announced the completion of a $10 million Series A preferred stock financing by Domain Associates....
More...
